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The A allele of the FRAS1-related extracellular matrix protein 3 (FREM3) rs7676614
single nucleotide polymorphism (SNP) was linked to major depressive disorder (MDD)
in an early genome-wide association study (GWAS), and to symptoms of psychomotor
retardation in a follow-up investigation. In line with significant overlap between age- and
depression-related molecular pathways, parallel work has shown that FREM3 expression
in postmortem human brain decreases with age. Here, we probe the effect of rs7676614
on amygdala reactivity and perceptual processing speed, both of which are altered in
depression and aging. Amygdala reactivity was assessed using a face-matching BOLD
fMRI paradigm in 365 Caucasian participants in the Duke Neurogenetics Study (DNS)
(192 women, mean age 19.7 ± 1.2). Perceptual processing speed was indexed by
reaction times in the same task and the Trail Making Test (TMT). The effect of rs7676614
on FREM3 mRNA brain expression levels was probed in a postmortem cohort of 169
Caucasian individuals (44 women, mean age 50.8 ± 14.9). The A allele of rs7676614
was associated with blunted amygdala reactivity to faces, slower reaction times in the
face-matching condition (p < 0.04), as well as marginally slower performance on TMT
Part B (p = 0.056). In the postmortem cohort, the T allele of rs6537170 (proxy for
the rs7676614 A allele), was associated with trend-level reductions in gene expression
in Brodmann areas 11 and 47 (p = 0.066), reminiscent of patterns characteristic of
older age. The low-expressing allele of another FREM3 SNP (rs1391187) was similarly
associated with reduced amygdala reactivity and slower TMT Part B speed, in addition
to reduced BA47 activity and extraversion (p < 0.05). Together, these results suggest
common genetic variation associated with reduced FREM3 expression may confer risk
for a subtype of depression characterized by reduced reactivity to environmental stimuli
and slower perceptual processing speed, possibly suggestive of accelerated aging.
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Introduction
Despite increasing sample sizes, case-control genome-wide
association studies (GWAS) of major depressive disorder
(MDD) have yielded inconclusive results, with few single
nucleotide polymorphisms (SNPs) surviving the commonly
accepted genome-wide significance threshold of p = 5 × 10−8
and even fewer withstanding the test of a full replication in
an independent sample (Wray et al., 2012; Major Depressive
Disorder Working Group of the Psychiatric GWAS Consortium
et al., 2013). The relative lack of success of these studies has been
at least partially attributed to the heterogeneity inherent to the
MDD diagnostic category (Major Depressive Disorder Working
Group of the Psychiatric GWAS Consortium et al., 2013).
Yet, despite the recognition in the literature of different MDD
subtypes with presumably different pathophysiologies (Kessing,
2007), few genetic association studies take this heterogeneity into
account, and those that do, have been inadequately powered to
detect subtype-specific associations (Major Depressive Disorder
Working Group of the Psychiatric GWAS Consortium et al.,
2013).
Despite these initial set-backs, several follow-up investigations
have resulted in partial replications or have linked suggestive
SNP “hits” to specific symptom dimensions or biological
endophenotypes, though not necessarily to the overall syndrome
(Sullivan et al., 2009; Rietschel et al., 2010; Kohli et al., 2011;
Kuehner et al., 2011; Li et al., 2013; Schuhmacher et al., 2013).
In light of the immense diagnostic, and presumably biological
heterogeneity of MDD, such partial replications and mechanistic
follow-up studies may in fact inform an improved understanding
of the etiology of specific subtypes of MDD as well as help
facilitate the delineation of distinct biological pathways of risk.
A SNP (rs7676614) within the human FRAS1-related
extracellular matrix protein 3, encoded by the FREM3 gene, was
among the top hits in an early GWAS of MDD, where the major
A allele was associated with nominally higher risk relative to
the minor G allele (p = 9.52 ×10−5 meta-analyzed across two
independent samples) (Muglia et al., 2010). Importantly, while
this SNP was not associated with MDD diagnosis in a follow-up
study, it was specifically and strongly linked to symptoms
of psychomotor retardation (Shi et al., 2012). Psychomotor
symptoms in depression can range from retardation to agitation
and have been proposed to constitute an important source of
disorder heterogeneity (Sobin and Sackeim, 1997; Leventhal
et al., 2008; Schrijvers et al., 2008). Thus, the association between
rs7676614 and symptoms of retardation may not only explain
the lack of a stronger link between the SNP and overall MDD
diagnosis, but also offer mechanistic clues as to the specific
biological pathway through which this SNP may increase MDD
risk.
A largely independent line of research drawing on human
postmortem gene expression data has demonstrated a significant
overlap between molecular pathways implicated in depression
and normal aging (Wolkowitz et al., 2010; Sibille, 2013).
Specifically, it has been proposed that MDD or risk thereof may
stem at least partially from molecular processes resulting in gene
expression patterns reminiscent of premature, or accelerated,
aging of the brain (Douillard-Guilloux et al., 2013; Sibille,
2013). Intriguingly, FREM3 is among the genes whose expression
declines as a function of normal aging (Glorioso et al., 2011).
This steady decline has been shown to occur in the amygdala
and the anterior cingulate cortex (ACC), both of which have
been extensively implicated in the pathophysiology of depression
(Davidson et al., 2002).While this prior work has used a relatively
small cohort enriched for individuals over the age of 50, thus
possibly not fully capturing age-related changes in expression
pattern occurring throughout the entire adult lifespan, it strongly
suggests FREM3 may contribute to age-related pathways of
depression risk. Furthermore, the retardation of psychomotor
function, in addition to being a symptom of a subtype of
depression, is also a concomitant of older age (Seidler et al.,
2010). Taken together, these data raise the intriguing possibility
that the A allele of the FREM3 rs7676614 polymorphism may
predispose to depression via an accelerated brain aging pathway,
or, alternatively, the minor G allele may be associated with
relative resilience to, or slowing of, the normal changes associated
with aging.
Depression and aging are both associated with profound
changes in cognitive and affective processing in the brain
(Milham et al., 2002; Whalen et al., 2002; Fitzgerald et al., 2008;
Disner et al., 2011; Kehoe et al., 2013; Kennedy et al., 2015).
A large body of work utilizing functional magnetic resonance
imaging (fMRI) in patients withMDDhas revealed dysregulation
within a corticolimbic circuitry involved in the perception and
regulation of emotion and affect, within which the amygdala
serves as a hub. Themajority of these studies demonstrate relative
amygdala hyperactivity in response to negative stimuli (Whalen
et al., 2002; Victor et al., 2010; Yang et al., 2010). However, a
notable minority of studies has associated depression (Thomas
et al., 2001) or depression risk (Wolfensberger et al., 2008)
with relatively blunted amygdala response to threat, suggesting
there may be a depression subtype associated with reduced
reactivity to environmental stimuli. Notably, amygdala reactivity
is also reduced in healthy older adults (Fischer et al., 2005,
2010; Tessitore et al., 2005). Consistent with molecular pathology
findings in depression (Douillard-Guilloux et al., 2013), it is
possible that a premature forward shift along this normal age-
related trajectory of corticolimbic functionmay contribute to risk
of depression or one of its subtypes. Conversely, factors that slow
progression along this trajectory may confer resilience.
In the current study, we leveraged data from the ongoing
Duke Neurogenetics Study (DNS) and a postmortem cohort,
to test the hypothesis that rs7676614 would modulate risk
of depression via accelerating normal age-related changes in
neuropsychological function and gene expression patterns.
Specifically, we hypothesized that, regardless of current
depressive symptomatology, the A allele would bias amygdala
reactivity, perceptual processing speed, and gene expression
toward a pattern reminiscent of older age. We further sought
to confirm the effect of age on FREM3 gene expression in the
current postmortem cohort, which is better powered to detect
trajectories of gene expression change across the entire adult
lifespan than previous ones (Erraji-Benchekroun et al., 2005;
Glorioso et al., 2011), while also extending the results to the
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orbitofrontal and ventrolateral prefrontal cortices (Brodmann
areas 11 and 47). Finally, we explored the possible involvement
of FREM3 in depression risk by linking additional functional
variation in the same gene (rs1391187) to behaviorally relevant
differences in in vivo brain function.
Methods
Participants
Neuroimaging and genetic data were derived from 365 non-
Hispanic Caucasian participants (192 women, mean age
19.76 ± 1.23) who had successfully completed the ongoing
Duke Neurogenetics Study (DNS) and whose BOLD fMRI
data survived a stringent multi-level quality control procedure
(Supplementary Methods). The DNS assesses a range of
behavioral and biological traits among young adult, university
students. All participants provided informed consent in
accordance with Duke University guidelines, and were
in good general health. All participants were free of the
following exclusionary criteria, as determined by self-report: (1)
medical diagnoses of cancer, stroke, diabetes requiring insulin
treatment, chronic kidney or liver disease, or lifetime history of
psychotic symptoms; (2) use of psychotropic, glucocorticoid, or
hypolipidemic medication; and (3) conditions affecting cerebral
blood flow and metabolism (e.g., hypertension). Participants
were also screened for DSM-IV Axis I and select Axis II
diagnoses (Antisocial and Borderline Personality Disorder) using
the eMINI (Sheehan et al., 1998). Current or lifetime diagnosis of
a disorder was not exclusionary. However, all participants were
free of psychotropic medication, including recreational drugs, at
the time of study participation. Notably, controlling for current
or past DSM-IV diagnosis did not significantly alter our results.
Thus, we report results from models not including diagnosis
as a covariate. Detailed diagnostic information can be found in
Supplementary Table 1.
BOLD fMRI Paradigm
Our amygdala reactivity paradigm has been described in detail
previously (Carré et al., 2013). Briefly, the amygdala reactivity
paradigm consists of 4 blocks of a face-processing task interleaved
with 5 blocks of a sensorimotor control task. During task
blocks, participants are simultaneously presented with three
faces (with neutral, angry, fearful, or surprised expressions) and
are asked to indicate which one of two faces shown in the
bottom of the screen is identical to a target face shown on top.
During control blocks, participants perform an analogous task
with simple geometric shapes. Here, we focused on amygdala
reactivity in the contrast of face blocks vs. control blocks (i.e.,
All Faces> Shapes). To ensure greater convergence between our
in vivo neuroimaging and our post-mortem data analyses, we
further probed the effect of genotype on activity in BA11/47,
corresponding to regions of the orbitofrontal cortex (OFC)
and ventrolateral prefrontal cortex (vlPFC). In a follow-up
exploratory analysis we probed genotype effects on threat-
specific amygdala reactivity in the Anger + Fear > Shapes
condition.
Perceptual Processing Speed
Perceptual processing speed was assessed using reaction times
(RT) recorded during the face and shape-matching task.
Notably, even though the stimuli remained on the screen for a
fixed amount of time to ensure uniform perceptual exposure,
participants were instructed to match the stimuli as quickly as
they can, while maintaining accuracy. RTs were recorded in all
trials. Accuracy was close to ceiling throughout the task, but was
slightly higher in the Faces (98.7%± 0.05), relative to the Shapes
(98.0% ± 0.05) condition (p < 0.001). Only RTs from correct
trials in both conditions were used in analyses.
To further probe perceptual and cognitive processing speed
we used the Trail Making Test (TMT, Bowie and Harvey, 2006).
This test is designed to measure processing speed, cognitive
flexibility as well as visuomotor skills. Part A of the TMT (Trails
A) asks participants to connect encircled numbers 1 through 25
sequentially on a piece of paper. In Part B of the TMT (Trails B)
participants connect encircled numbers and letters, in numerical
and alphabetical order, respectively, while alternating between
numbers and letters. Numbers and letters are distributed on the
paper in a semi-random fashion that allows them to be connected
without drawing overlapping lines. The primary outcome of
interest in both Parts A and B of this test is the overall time it
takes for participants to complete the task. Trails A is believed
to gauge visual search and motor speed skills, while Trails B is
believed to tap into higher-level cognitive skills, such as mental
flexibility. Outliers greater than 60 s on Trails A (n = 2) or 90 s
(n = 3) on Trails B were removed from analyses. Number of
errors was controlled for alongside gender and age in all analyses
involving the TMT.
Self-report and Behavioral Measures
Recent and early life stress were assessed using a modified version
of the Life Events Scale for Students (LESS, Nikolova et al., 2012)
and the Childhood TraumaQuestionnaire (CTQ, Bernstein et al.,
2002), respectively. Current depression and anxiety were assessed
using the Center for Epidemiological Studies-Depression (CES-
D, Radloff, 1977) scale and the short form of the Mood and
Anxiety Symptom Questionnaire (MASQ, Watson et al., 1995).
To assess the effects of genotype on personality traits which may
predispose to or protect against depression, we analyzed response
data on the NEO personality inventory (Costa and McCrae,
1992). We focused specifically on the neuroticism (NEON) and
extraversion (NEOE) factors, which have been most extensively
mapped onto specific neurobiological substrates (Wright et al.,
2006; Aghajani et al., 2014), as well as differential risk or resilience
for psychopathology (Campbell-Sills et al., 2006; Bienvenu et al.,
2007; Lamers et al., 2012). The Wechsler Abbreviated Scale of
Intelligence™ (WASI™, Wechsler, 1999) was administered to
assess general intelligence, which was used as a covariate in
analyses involving the TMT.
Genotyping
Genotyping of the in vivo cohort was facilitated through
23andMe (23andMe, Inc., Mountain View, CA). Genomic DNA
from all participants was isolated from buccal cells and leukocytes
derived from Oragene DNA self-collection kits (DNA Genotek,
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Inc., Kanata, Ontario, Canada) customized for 23andMe. DNA
extraction and genotyping were performed at the National
Genetics Institute (NGI), a CLIA-certified clinical laboratory and
subsidiary of Laboratory Corporation of America. The Illumina
Omni Express Plus chip (Illumina, Inc., San Diego, CA, USA)
and a custom array containing an additional∼300,000 SNPs were
used to provide genome-wide data (Eriksson et al., 2010; Do
et al., 2011; Tung et al., 2011). The Illumina Omni Express Plus
chip included the rs7676614 SNP. In our final sample, genotype
frequencies for rs7676614 did not deviate from Hardy-Weinberg
equilibrium (169 A homozygotes, 166 AG heterozygotes, 30 G
homozygotes, χ2 = 1.49; p = 0.22). Furthermore, the allele
frequencies in the current sample (A allele: 0.31, G allele: 0.69)
were similar to those reported for populations of European
ancestry (current sample: A allele frequency 0.31, G allele: 0.69;
reference sample from 1000 Genomes, A allele: 0.35, G allele:
0.65).
Postmortem Gene Expression
The postmortem cohort has been described in detail previously
(Seney et al., 2013). Briefly, data were derived from 211
individuals (44 women, mean age 50.76 ± 14.91, range
16–96) with no history of neuropsychiatric illness. After
consent from next-of-kin was obtained, postmortem brains were
collected in the Allegheny County Coroner’s Office (Pittsburgh,
PA) using procedures approved by University of Pittsburgh’s
Institutional Review Board and Committee for Oversight of
Research Involving the Dead. The absence of psychiatric
DSM-IV diagnosis was determined based on psychopathology,
medical and social histories, as well as history of substance
abuse. Individuals were also screened for the absence of
neurodegenerative disorders by neuro-pathological examination.
Total RNA was extracted from frozen samples using
TRIzol R© (Invitrogen Life Technologies, Carlsbad, CA, USA)
followingmanufacturer’s protocol (see SupplementaryMethods).
Technical parameters of all RNA samples were within the
range of desired RNA quality for large-scale gene expression
studies (RNA integrity number: 8.02 ± 0.74, RNA ratio:
1.53 ± 0.35). RNA samples were processed for microarray
by the Gene Expression & Genotyping Core Facility at Case
Western Reserve University. Briefly, with 150 ng of total RNA,
cDNA was synthesized by Ovation PicoSL WTA System V2
and labeled with Encore Biotin Module (both from NuGEN
Technologies, San Carlos, CA). 2.5µg of cDNA was hybridized
on Affymetrix R© Human Gene 1.1 ST arrays (Affymetrix,
Santa Clara, CA), covering over 30,000 coding transcripts.
Array hybridization, washing, and staining were conducted
on GeneTitan R© (Affymetrix) according to the manufacturer’s
protocol. Gene expression values were extracted via Expression
Console build 1.2.1.20 using RMA method and quantile-
normalization to eliminate batch effects. Gene expression probes
were processed in gene-level and converted to log2 scale to
perform further analysis. One coding transcript corresponding
to the FREM3 gene was represented on the array. Analyses were
restricted to Caucasian individuals, whose samples passed quality
control (n = 169, 44 women, mean age 50.8 ± 14.9; see also
Supplementary Methods).
Total DNA was extracted from fresh frozen brain samples
with Qiagen DNA mini kit following manufacturer’s protocol.
Genotype calls were generated using Affymetrix Genotyping
Console version 4.1.3 by a Birdseed v2 algorithm, which uses
EM to drive maximum likelihood fit of two dimensional
Gaussian mixture models. As the FREM3 rs7676614 SNP was
not available on the Affymetrix SNP Array 6.0, a perfect proxy
SNP, rs6537170 (R2 = 1.00, D′ = 1.00), was identified using
data from the 1000 Genomes project (Genomes Project et al.,
2012) accessed via the online SNAP Proxy Search Tool of the
Broad Institute (Johnson et al., 2008). This proxy SNP was used
in all analyses involving postmortem samples. We probed the
effect of rs6537170 on FREM3 mRNA levels in samples derived
from both BA11 and BA47 in 169 Caucasian individuals. An
additional 57 SNPs within or near the FREM3 gene (50 kb up-
or downstream) were examined for association with FREM3
expression (Supplementary Table 2). To further explore the
involvement of FREM3 in depression-related phenotypes, we
selected the SNP with the strongest impact on FREM3 expression
(rs1391187) and evaluated its effect (via proxy SNP rs1909022,
R2 = 1.00, D′ = 1.00, 1000 Genomes) on the same in vivo neural
and behavioral phenotypes tested for rs7676614.
Statistical Analyses
Three sets of models were tested for all in vivo phenotypic
associations: additive, minor allele dominant, and minor allele
recessive. In the additive model, linear regressions using number
of major alleles as a predictor of amygdala reactivity or perceptual
processing time were conducted in IBM SPSS Statistics 21
(IBM, Armonk, NY). In the dominant model, ANOVAs using
genotype (minor allele carrier vs. major allele homozygote, or
major allele carrier vs. minor allele homozygote) predicting
outcomes were used. In the postmortem cohort, a general
power function model was used to assess the effects of age on
gene expression scores residualized for potential confounding
covariates (e.g., postmortem interval, pH, RNA integrity number,
race, and gender). This model was adopted in order to allow
for the detection of non-linear age-related trajectories. The
effects of genotype on expression was tested using FREM3
expression scores residualized for those potential confounds in
addition to estimated non-linear age effect, ethnic background
(Price et al., 2006), and 16 principal components derived from
transcriptome-wide analysis of gene expression data (Liang et al.,
2013). Mediation analyses in the in vivo cohort were conducted
using Models 4 and 6 of the PROCESS macro in SPSS (Hayes,
2013). Bootstrapped bias-corrected confidence intervals (CIs) for
each indirect effect were generated using 5000 bootstrapping
iterations.
Results
Main Effect of Task and Demographics
Consistent with prior research (Nikolova and Hariri, 2012;
Swartz et al., 2015), our task resulted in significant amygdala
reactivity bilaterally for the Faces> Shapes contrast (Figure 1A).
Further analyses revealed significant activity in BA11 and BA47
(Figure 1B). Partially confirming prior work (Nikolova et al.,
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2012), we found that men had greater amygdala reactivity than
women in the left [t(363) = 2.54, p = 0.012], but not the
right hemisphere [t(363) = 1.30, p = 0.193]. When gender
was accounted for, amygdala reactivity was further modulated
by age, such that older participants showed a trend towards
lower amygdala reactivity (left hemisphere: b = −0.087, p =
0.096; right hemisphere: b = −0.090, p = 0.085). There
were no differences in age, gender composition and estimated
IQ among genotype groups (Table 1). However, in light of the
effects of gender and age on amygdala reactivity, all analyses were
conducted with and without gender and age as covariates.
Genetic Effects on Amygdala Reactivity
FREM3 rs7676614 genotype modulated amygdala response, such
that increasing number of major (A) alleles was associated
with significantly decreased amygdala reactivity in the right
(b = −0.109, p = 0.038), and marginally decreased reactivity in
FIGURE 1 | Statistical parametric map illustrating mean bilateral
activity for the Faces > Shapes contrast. Activation clusters are presented
for (A) the amygdala (peak voxel activation in the left hemisphere: x = −22,
y = −6, z = −18, t = 28.55, p < 0.000001, kE = 179; right hemisphere:
x = 28, y = −4, z = −20, t = 32.82, p < 0.000001, kE = 199) and (B)
Brodmann areas 11 and 47 (peak voxel activation in the left hemisphere:
x = 58, y = 28, z = 0, t = 15.60, p < 0.000001, kE = 143; right hemisphere:
x = −52, y = 40, z = −2, t = 14.47, p < 0.000001, kE = 24). The clusters are
overlaid onto canonical structural brain images in the coronal plane (y = −2)
and axial planes (z = −12), respectively.
the left (b = −0.101, p = 0.055) hemisphere (Figures 2A,C).
The effect was significant bilaterally when covarying for gender
and age (right hemisphere: b = −0.116, p = 0.026; left
hemisphere: b = −0.110, p = 0.035). When a G allele
dominant model was tested, individuals homozygous for the
risk A allele were found to have relatively reduced amygdala
reactivity for the All Faces > Shapes contrast, when compared
to carriers of the G allele. The effect was stronger on the right
side [left hemisphere: F(1, 363) = 3.06, p = 0.081; right
hemisphere: F(1, 363) = 4.46, p = 0.035; Figures 2B,D]. The
significance of these results did not change when gender and
age were controlled for [left hemisphere: F(1, 361) = 3.85,
p = 0.051; right hemisphere: F(1, 361) = 5.20, p = 0.023].
Notably, no significant effect of genotype emerged in threat-
specific contrasts (p > 0.11), suggesting a broader hypo-
reactivity of the amygdala to environmental salience rather
than a threat-specific blunting of amygdala response. Consistent
with this conceptualization, neither current, nor early life
stress interacted with FREM3 genotype to predict amygdala
response (p > 0.12). Importantly, there were no differences
in self-reported early or recent stress between genotype groups
(p > 0.10).
An exploratory whole-brain analysis revealed no effect of
FREM3 rs7676614 genotype on activity in any other brain region.
Further region of interest analyses revealed no effect on activity
in BA11 and BA47 (p > 0.10).
Genetic Effects on Processing Speed
Reaction Times
In addition to its effect on amygdala response, FREM3 genotype
was found to modulate processing speed as indexed by
behavioral measures collected during the BOLD fMRI paradigm.
Specifically, increasing number of A alleles was associated with
slower RTs in the Faces (b = −0.107, p = 0.035; controlling
for gender and age: b = −0.109, p = 0.032), but not in
the Shapes (p > 0.2; Figures 3A,C) condition. Similarly, G
allele carriers had faster RTs relative to A homozygotes in the
Faces [A homozygotes: 1.22 ± 0.28 s; G carriers: 1.15 ± 0.27 s;
F(1, 363) = 4.89, p = 0.028; controlling for gender and age:
F(1, 361) = 5.00, p = 0.026], but not in the Shapes blocks [A
TABLE 1 | Summary of demographic characteristics and estimated IQ represented as a function of FREM3 rs7676614 genotype.
FREM3 rs7676614 p p (additive)
GG AG AA
n 30 166 169 ‘ ‘
Male/Female 14/16 76/90 83/86 0.827 ‘
Age (mean ± SD) 19.83 ± 1.26 19.83 ± 1.25 19.67 ± 1.20 0.499 0.278
Estimated IQ 125.33 ± 6.47 123.70 ± 7.12 123.26 ± 7.70 0.358 0.200
CTQ 31.13 ± 6.64 31.09 ± 6.70 31.85 ± 8.23 0.632 0.390
LESS 3.97 ± 2.39 3.98 ± 2.74 4.49 ± 3.26 0.270 0.138
NEO-N 77.83 ± 23.64 82.58 ± 20.59 82.50 ± 24.10 0.549 0.490
NEO-E 125.30 ± 20.08 120.81 ± 21.40 122.09 ± 20.92 0.543 0.839
The table includes p-values from both a mean comparison (ANOVA) and an additive (regression) model.
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FIGURE 2 | Effects of FREM3 rs7676614 genotype on amygdala reactivity. Increasing number of A alleles was associated with decreased amygdala reactivity in
the left (A) and right (C) hemisphere. In a G allele dominant model, A homozygotes showed a trend toward decreased amygdala reactivity in the left hemisphere (B)
and significantly decreased amygdala reactivity than G carriers in the right hemisphere (D). Error bars represent standard error of the mean. *p < 0.05, #p < 0.10,
a.u. = arbitrary units.
FIGURE 3 | Effects of FREM3 rs7676614 genotype on reaction times in the perceptual face matching task. Increasing number of A alleles was associated
with slower reaction times in the Faces (A), but not the Shapes (C) condition. These results were confirmed in a G allele dominant model, where A homozygotes
showed slower reaction times than G carriers in the Faces (B) but not the Shapes condition (D). Error bars represent standard error of the mean. *p < 0.05,
#p < 0.10.
Frontiers in Psychology | www.frontiersin.org 6 September 2015 | Volume 6 | Article 1377
Nikolova et al. FREM3, aging, and depression risk
homozygotes: 0.96 ± 0.19 s; G carriers: 0.93 ± 0.19 s; F(1, 363) =
1.97, p = 0.161; controlling for gender and age: F(1, 361) = 2.22,
p = 0.137; Figures 3B,D]. Notably, RTs were slower overall in
the Faces, compared to the Shapes condition, possibly reflecting
the relative perceptual complexity of the stimuli to be matched
[Faces: 1.80 ± 0.28 s; Shapes: 0.94 ± 0.19 s F(1, 361) = 0.826,
p < 0.0001]. Thus, perhaps the lack of genotype effect on RT
in the Shapes condition may reflect performance ceiling effects.
There were no differences in accuracy between genotype groups
(p > 0.27).
Trail Making Test
To further probe the effect of FREM3 genotype on perceptual
processing speed, we compared genotype groups on their
performance on the TMT Parts A and B, administered outside
the scanner. Despite A homozygotes’ being nominally slower
to complete Trails A, the difference in performance reached
only trend levels [A homozygotes: 22.71 ± 6.60 s; G carriers:
21.64 ± 5.79 s, F(1, 355) = 3.11, p = 0.079; Figure 4A]. Larger
genotype differences emerged in Trails B performance, where
A homozygotes were slower to complete the task by an average
of 2.14 s [A homozygotes: 46.02 ± 12.73 s; G carriers: 43.89 ±
11.03 s, F(1, 355) = 3.69, p = 0.056; Figure 4B]. No additive effect
of number of A alleles was observed on either task (p > 0.12).
Notably, there were no genotype effects on number of errors in
FIGURE 4 | Effects of FREM3 rs7676614 genotype on TMT
performance. Relative to G carriers, A allele homozygotes showed a trend
toward slower performance in both Part A (A) and Part B (B) of the TMT. Error
bars represent standard error of the mean. *p < 0.05, #p < 0.10.
either Trails A or Trails B (p > 0.39) and the differences in speed
occurred in the absence of genotype differences in estimated IQ
(Table 1). Furthermore, the effects remained trending when IQ
was controlled for alongside gender and age (Trails A: p = 0.089;
Trails B: p = 0.076).
There was no association between amygdala reactivity and
processing speed, as reflected by either RT or TMT, either in the
overall sample or for any specific genotype group (p > 0.10).
Postmortem Gene Expression
We next probed the effect of age and FREM3 genotype on FREM3
mRNA levels in human postmortem tissue. Age was associated
with a robust decline in FREM3 expression in both BA11
and BA47 following a near-linear trajectory (Figures 5A,B). In
addition, our proxy SNP showed a trending effect, such that
the major allele was associated with relatively reduced gene
expression in both BA11 (p = 0.062; Figure 5C) and BA47
[Figure 5D, p = 0.08; p = 0.066 based on an adaptively-
weighted (AW) meta-analysis (Li and Tseng, 2011) across both
regions] in a pattern reminiscent of that seen in older age.
Importantly, these results were adjusted for gender and estimated
effects of chronological age at time of death.
Additional FREM3Variants
To further explore the potential involvement of the FREM3
gene in regulating depression-relevant neural and behavioral
phenotypes, we identified rs1391187 as the SNP most strongly
modulating FREM3 expression across both BA11 (p =
2.17 ×10−5, Figure 5E) and BA47 (p = 2.47 × 10−6, Figure 5F,
Supplementary Table 2) in our postmortem cohort, and tested
its effects (via proxy SNP rs1909022, R2 = 1.00, D′ = 1.00), on
neural activity and perceptual processing speed in our in vivo
cohort. In striking similarly to rs7676614, the lower-expressing
major allele at rs1391187/rs1909022 was also associated
with reduced amygdala reactivity bilaterally (left amygdala:
b = −0.167; p = 0.001; right amygdala: b = −0.159; p = 0.002;
Figures 6A,B) as well as slower speed in the TMT Part B (b =
0.114; p = 0.025, Figure 7A). These effects remained significant
when controlling for gender and age (left amygdala: b = −0.170;
p = 0.001, right amygdala: b = −0.162; p = 0.002; Trails B,
adjusted for IQ: b = 0.111; p = 0.028). Notably, there were no
significant differences in gender composition or estimated IQ
among rs1909022 genotype groups (Table 2). While there was
a main effect of age (p = 0.045), such that heterozygotes were
slightly but significantly older than GG homozygotes (p = 0.024,
LSD-corrected), there was no linear association between number
of minor/major alleles and age (p = 0.486).
There was no effect of rs1391187/rs1909022 genotype on RT
in the Faces or Shapes matching condition or the TMT Part A
(p > 0.20). Genotype groups did not differ on self-reported stress
(p > 0.30) and stress did not interact with rs1391187/rs1909022
genotype to predict amygdala reactivity or processing speed (p >
0.10). Notably, rs1391187/rs1909022 and rs7676614 are not in
high LD (R2 = 0.182, D′ = 0.481, 1000 Genomes) and did not
interact with each other to predict any phenotype of interest (p >
0.19), suggesting their contributions to differences in FREM3
expression and function may be independent.
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FIGURE 5 | Age was associated with a robust decrease in FREM3 gene expression in both BA11 (A) and BA47 (B). In addition, the major T allele of
rs6537170 (proxy for rs7676614), was associated with trend-level reductions in gene expression in BA11 (C) and BA47 (D). Finally, the major G allele of rs1391187
was also associated with decreased gene expression in BA11 (E) and BA47 (F). Each box in (C–F) represents the interquartile range of the data and the whiskers
extend to the most extreme data point which is no more than 1.5 times the interquartile range from the box.
An exploratory whole-brain analysis revealed no effect of
FREM3 rs1391187/rs1909022 genotype on activity in any other
brain region. However, ROI analyses revealed that the major
allele was associated with significantly decreased activity in BA47
(Figures 6C,D).
Link to Self-report Measures
Although there were no differences in measures of current
mood and neuroticism between genotype groups as defined by
either SNP (p > 0.10), increasing number of major alleles
at rs1391187/rs1909022 was associated with lower extraversion,
as assessed by the NEOE (no covariates: b = −0.121,
p = 0.021, with covariates; b = −0.124, p = 0.017,
Figure 7B). This effect was driven primarily by the Activity
subscale (no covariates: b = −0.143, p = 0.006; with covariates:
b = −0.145, p = 0.005). Furthermore, NEOE was positively
correlated with BA47 activity in the left hemisphere, such
that BA47 activity negatively mediated the association between
number of rs1391187/rs1909022 major alleles and NEOE scores
(Figure 8A). Finally, there was a positive correlation between
amygdala reactivity and BA47, such that when amygdala and
BA47 activity were entered sequentially into a mediation model,
they were both found to be significant mediators of the link
between rs1391187/rs1909022 genotype and NEOE (Figure 8B).
Importantly, a model where amygdala reactivity was entered
as a mediator more proximal to extraversion did not result in
significant mediation (b = 0.098, SE = 0.264, 95% CI: –0.366,
0.704).
Discussion
In this study we show that the major A allele of the FREM3
rs7676614 polymorphism is associated with blunted amygdala
reactivity to socially salient stimuli, as well as reduced processing
speed, as indexed by slower reaction time in a perceptual
matching task and visuomotor performance in the Trails Making
Test. These results are consistent with prior epidemiological
and clinical studies associating the A allele with relatively
heightened risk of depression (Muglia et al., 2010) as well as
symptoms of psychomotor retardation (Shi et al., 2012). We
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FIGURE 6 | Effects of FREM3 rs1909022 genotype (proxy for rs1391187) on amygdala and BA47 activity (A–D). Increasing number of major (G) alleles was
associated with reduced reactivity in both brain regions and hemispheres. *p < 0.05, #p < 0.10, a.u. = arbitrary units.
FIGURE 7 | Effects of FREM3 rs1909022 genotype on TMT Part B performance and extraversion. Increasing number of major (G) alleles was associated with
relatively slower TMT performance (A) and lower levels of extraversion (B). *p < 0.05.
also confirm and extend prior basic molecular work (Glorioso
et al., 2011) by showing that FREM3 expression in postmortem
human prefrontal cortex (BA11 and BA47) tissue robustly
decreases with age. Moreover, we show that the A allele of
rs7676614 is associated with a trend toward reduced FREM3
gene expression, shifting this molecular phenotype toward
a pattern reminiscent of older age. Finally, we demonstrate
convergent in vivo phenotypic effects of rs1391187, the SNP
showing the strongest modulatory impact on FREM3 expression
in our postmortem cohort. Specifically, we show that the
lower-expressing major allele of rs1391187 (assessed via proxy
SNP rs1909022) is associated with relatively reduced amygdala
reactivity, slower visuomotor performance in the TMT Part B,
blunted activity in BA47, as well as reduced extraversion. Taken
together, and in light of prior work demonstrating reduced
amygdala reactivity and slower processing speeds in healthy
older adults (Tessitore et al., 2005), our results suggest that the
major alleles at both rs7676614 and rs1391187/rs1909022 may
increase depression risk by precipitating the premature activation
of biological pathways implicated in the normal molecular
aging of the brain (Sibille, 2013). Conversely, the minor alleles
at these loci may be associated with relative resilience to
depression via a comparative slowing down of normal age-related
processes.
The conceptual link between depression and accelerated
aging (Wolkowitz et al., 2011; Sibille, 2013) may seem at odds
with epidemiological data suggesting MDD is diagnosed less
frequently in older, relative to young adults (Hasin et al.,
2005). This seeming inconsistency may be due to the fact that
late-life depression has a unique symptom profile, only partially
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TABLE 2 | Summary of demographic characteristics and estimated IQ represented as a function of FREM3 rs1909022 genotype.
FREM3 rs1909022 p p (additive)
GG AG AA
n 111 197 57 ‘ ‘
Male/Female 49/62 100/97 24/33 0.367 ‘
Age (mean ± SD) 19.58 ± 1.18 19.90 ± 1.24 19.60 ± 1.24 0.045 0.486
Estimated IQ 123.12 ± 6.96 124 ± 7.51 123.37 ± 7.57 0.575 0.651
CTQ 31.67 ± 7.34 31.11 ± 7.49 32.18 ± 7.48 0.591 0.857
LESS 4.16 ± 2.97 4.23 ± 3.13 4.26 ± 2.43 0.974 0.821
NEO-N 84.19 ± 23.90 81.51 ± 21.67 80.40 ± 22.66 0.494 0.253
NEO-E 119.11 ± 19.55 121.67 ± 21.88 127.35 ± 20.23 0.055 0.021
The table includes p-values from both a mean comparison (ANOVA) and an additive (regression) model. Significant values are highlighted in bold font.
FIGURE 8 | Results from mediation models wherein activity in BA47 mediated the association between rs1909022 genotype and extraversion scores
by itself (A) or in conjunction with amygdala reactivity (B). Raw regression coefficients are presented for each path, along with standard errors in parentheses.
Bootstrapped 95% confidence intervals are presented for the indirect (mediation) effects. **p < 0.005, *p < 0.05, #p < 0.10. CI, Confidence interval.
overlapping with that seen in young and middle-aged adults. For
example, depressed older adults are less likely to report affective
symptoms, which are heavily weighted in DSM criteria for MDD
(Fiske et al., 2009). In fact, older adults generally report greater
well-being (Carstensen et al., 2011). However, they are more
likely to experience depression-related cognitive and somatic
symptoms, including psychomotor retardation, as well as loss
of interest in normal daily activities (Fiske et al., 2009). These
symptoms may in turn contribute to subsyndromal depression,
which may cause significant impairment in the quality of life of
the elderly, without necessarily meeting DSM diagnostic criteria.
Because depressive symptoms in the elderly are frequently
distinct from those experienced by younger individuals and
tend to be misattributed or overattributed to physical illness or
bereavement, depression or subsyndromal depressive symptoms
which impair quality of life in the elderly may be underdiagnosed
and untreated (VanItallie, 2005). Moreover, early- and late-life
onset depression likely represent distinct biological entities with
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different underlying pathophysiologies. Our findings conceivably
tap into the pathophysiology of late-life onset depression, risk for
or resilience to which may, however, be detectable at a younger
age (Douillard-Guilloux et al., 2013).
Abnormally increased (Whalen et al., 2002; Victor et al.,
2010; Yang et al., 2010) or decreased (Thomas et al., 2001;
Lawrence et al., 2004; Wolfensberger et al., 2008) amygdala
reactivity to threat or other emotionally salient stimuli have
both been implicated in depression or risk thereof. The mixed
nature of these findings may reflect distinct depression subtypes
or pathways of risk. Heightened amygdala reactivity may be
associated with increased sensitivity to environmental events and
thus particularly predispose to depression in the context of stress
(Caspi et al., 2010). In contrast, a relative blunting of amygdala
response may reflect a reduced reactivity to environmental
salience, which can be a risk factor for depression in its own
right (Rottenberg et al., 2005; Bylsma et al., 2008). Our results
suggest that the low-expressing major alleles at both rs7676614
and rs1391187/rs1909022 may confer risk for a subtype of MDD
via the latter pathway. This notion is further strengthened by
the fact that we observed no significant interaction between
genotype and self-reported stress in predicting amygdala
reactivity. Finally, this conceptualization is also consistent with
a recent twin study which demonstrated that non-overlapping
contributions of genetic and environmental factors to depression
risk are associated with amygdala hypo- and hyper-reactivity,
respectively (Wolfensberger et al., 2008). Taken together, these
data suggest that FREM3 functional variation may uniquely
contribute to risk for a subtype of depression that is not
precipitated by stress, but is rather a more proximal result of
genetic influences. It should, however, be noted that effects of
early life stress may emerge in a sample reporting higher and/or
more variable levels of childhood trauma.
Importantly, FREM3 is among the genes whose expression in
the amygdala and ACC has previously been shown to decrease
as a function of age (Glorioso et al., 2011). However, this prior
work has used a cohort which may have been underpowered to
detect changes in gene expression occurring across the entire
adult lifespan. Here, using a cohort spanning the entire adult
age range (16–96 years old), we extend these prior findings by
reporting a robust and highly significant age-associate decrease
in FREM3 expression in Brodmann areas 11 and 47—regions
broadly overlapping with the orbitofrontal cortex (OFC) as well
as the ventrolateral prefrontal cortex (vlPFC), both of which have
previously been implicated in depression pathophysiology and
risk (Rogers et al., 2004; Stuhrmann et al., 2011).
Extensive prior work has shown that a shift toward a
premature activation of age-related molecular pathways may
increase risk for depression, among other neuropsychiatric
disorders (Douillard-Guilloux et al., 2013; Sibille, 2013). In the
current study, we report that the rs7676614 A allele, as indexed
by the major allele of the proxy SNP rs6537170, is associated
with a trend toward decreased FREM3 expression in postmortem
human brain tissue, independent of chronological age. This
finding suggests that the A allele may predispose to depression via
shifting FREM3 expression to a pattern reminiscent of that seen
in older age. Conversely, the minor G allele may be associated
with relative resilience to the activation of these pathways and
effectively contribute to a protective “slowing down” of normal
age-related changes. Consistent with this conceptualization, one
prior study has demonstrated a link between normal aging and
the same in vivo phenotypic patterns we associated with the A
allele (Tessitore et al., 2005). Specifically, using a BOLD fMRI
paradigm similar to the one employed here, this study showed
a relative reduction in amygdala reactivity and a concomitant
slowing of face- but not shape-matching reaction times in older,
relative to young, adults (Tessitore et al., 2005). Importantly, and
in line with the current findings, this occurred in the absence of
any differences in face or shape matching accuracy. Phenotypic
convergence between older adults and carriers of the rs7676614
A allele is particularly remarkable in light of the fact that our
sample consisted exclusively of young adults between the ages of
18 and 22.
The finding of slower reaction times in the face-matching
condition in individuals with the rs7676614 A allele is further
consistent with prior associations of the same allele and
symptoms of psychomotor retardation (Shi et al., 2012).
Furthermore, we found convergent effects of genotype on
performance in the TMT, which is another index of psychomotor
function. Importantly, we found a stronger genotype effect on
performance in Trails B than in Trails A. Part A of the TMT
is generally interpreted as a purer measure of motor function,
while Part B taps into more complex visuomotor skills and task
switching (Bowie and Harvey, 2006). The stronger genetic effect
we observed in Part B, relative to Part A, suggests that rs7676614
may modulate higher-order cognitive processing of perceptual
stimuli, rather than motor function alone. This notion is also
consistent with the specificity of the rs7676614 effects on reaction
times to the more perceptually and cognitively challenging face-
matching condition, rather than the shape-matching condition of
our amygdala reactivity paradigm.
While we found that the major allele of rs1391187/rs1909022,
which is even more strongly linked to reduced FREM3
expression, is similarly associated with reduced amygdala
reactivity and slower TMT Part B performance, we found no
effect of rs1391187/rs1909022 on RT in the Face or Shape
matching condition or TMT Part A. It is possible that this SNP,
due to its stronger impact on FREM3, may even more selectively
impact complex, relative to simple, visuomotor tasks. The
partial discrepancy in phenotypic association between rs7676614
and rs1391187/rs1909022 may also be attributed to differential
LD patterns with additional variants, perhaps impacting the
expression of neighboring genes.
Despite the effect of genotype on both neural reactivity and
processing speed, we did not observe an association between
TMT speed and RT and activity in either amygdala or BA11/47.
Even though we investigated the effects of our SNPs of interest
on gene expression only within regions of the OFC and vlPFC,
FREM3 is expressed in multiple brain regions (Hawrylycz et al.,
2012). Thus, it is possible that the genetic effects on processing
speed are primarily mediated through brain regions or systems
not directly activated by our fMRI paradigm.
Importantly, we show that rs1909022, the SNP with a
more robust effect on postmortem FREM3 expression, is not
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only associated with differential amygdala response, but also
modulates activity in regions of the OFC and vlPFC overlapping
BA47. Specifically, we demonstrate that the low-expressing major
allele is associated with blunted response to salient facial affect
cues in BA47. Prior work has shown decreased OFC activity
to negative (sad and angry) facial expressions in MDD (Lee
et al., 2008), which may at least partially account for the deficits
in emotion recognition and reactivity observed in currently
depressed individuals (e.g., Persad and Polivy, 1993; Asthana
et al., 1998). Other studies demonstrate OFC hyporeactivity
may persist after disorder remission, but is remediated by
acute administration of the antidepressant citalopram (Anderson
et al., 2011). Additional research suggests that BA47 may be
involved in selectively incorporating emotion into decision
making (Beer et al., 2006). Specifically, activity in this region
has been shown to increase when incorporating relevant negative
emotional information into behavior, as well as when successfully
inhibiting irrelevant negative information (Beer et al., 2006).
Thus, hypoactivity in the same region may be associated with
maladaptive use of emotion to guide behavior and constitute
a risk factor for the development of depression. Furthermore,
additional prior MRI research indicates that the structural and
functional properties of the OFC may be particularly vulnerable
to age-related decline, relative to other parts of the PFC (Lamar
and Resnick, 2004; Resnick et al., 2007).
In addition to the effects of rs1909022 genotype on BA47
activity, we also observed a positive correlation between BA47
activity and extraversion. Prior work has demonstrated that
higher extraversion may be protective against MDD, as well as
psychopathologymore broadly (Campbell-Sills et al., 2006). This,
together with the fact that we associated themore common alleles
at both loci with a relative blunting of neural reactivity, as well as
slower processing speed, lends support to the conceptualization
that the minor alleles may in fact be conferring relative resilience
against depression- and age-related processes above and beyond
what may be a normal “baseline” phenotype associated with the
major alleles.
We further demonstrated that there was a positive correlation
between amygdala response and BA47 activity, and, when taken
together, these neural phenotypes both mediated the association
between rs1909022 genotype and extraversion. The convergent
effects of rs1909022 on both neural phenotypes, as well as their
joint mediation effect, suggest that functional variation impacting
FREM3 expression likely modulates activity in multiple brain
regions. Future work applying functional connectivity analytic
approaches to task-based or resting state brain activity on the
network level is likely to shed additional light on the full scope
of these effects.
It should be noted that despite the fact that we observed a
main effect of task, as well as an effect of rs1391187/rs1909022
genotype on gene expression, in both BA47 and BA11, we showed
an effect of genotype on activity in BA47, but not BA11. Given
the more ventral position of BA11, this region is more prone to
signal dropout due to its proximity to tissue boundaries. Thus,
it is possible that the most strongly activated and functionally
relevant regions within BA11 were not adequately covered by our
BOLD fMRI sequence. Future studies using imaging sequences
optimized for coverage in the ventral OFC are likely to shedmore
light on the relative specificity of these and similar findings to
lateral vs. more ventral regions of the OFC.
Critically, we found no direct link between genotype and
current depressive or anxious symptomatology. However, it
should be noted that our in vivo sample consisted of high-
functioning young adults attending a competitive university.
Thus, it is possible they are a particularly resilient population with
relatively limited variability in depressive and anxious symptoms.
Similarly, our postmortem sample contained individuals free of
neuropsychiatric illness. In light of these sample characteristic,
it might be reasonable to suggest that the genetic effects we
observe on amygdala reactivity, perceptual processing speed, as
well as gene expression, may reflect a latent vulnerability, which
may only lead to disorder in the context of additional risk
factors, including, but not limited to, increasing chronological
age. Importantly, we did observe a link between the major allele
of rs1391187/rs1909022 and the personality trait extraversion,
partially mediated via differences in BA47 activity. Given prior
links between extraversion and resilience to psychopathology
independent of risk conferred by other personality traits
(Campbell-Sills et al., 2006), our results may reflect a resilience
phenotype associated with the high-expressing, rather than
a vulnerability phenotype associated with the low-expressing
FREM3 alleles. Future studies utilizing prospective longitudinal
designs, especially in cohorts enriched in elderly subjects and/or
for MDD-related pathology, will be necessary to ascertain the
validity of this notion.
The molecular mechanisms underlying the associations
reported here have yet to be elucidated. The human FREM3 gene
codes for an extracellular matrix protein belonging to the same
family as FRAS1, FREM2, and QBRICK/FREM1, which have
been implicated in Fraser syndrome—a disorder characterized
by severe congenital malformations in the development of
the nose, ears, and throat, as well as mental retardation (van
Haelst et al., 2007). However, no evidence has directly linked
FREM3 to Fraser syndrome and additional research in mouse
models suggests the murine Frem3 gene shows distribution
patterns distinct from those of Frem1 and Frem2 (Kiyozumi
et al., 2007). As an extracellular matrix protein expressed in the
brain, FREM3 is likely implicated in cell–cell interactions and
maintaining the structural and functional integrity of nervous
tissue. Thus, it is likely to be involved in neural development
and function. Importantly, the extracellular matrix and its
associated proteins have been shown to play an important role
in brain aging (Morawski et al., 2014). Consistent with this,
additional extracellular matrix proteins such as reelin also show
strong, albeit less significant, age-related trajectories (Erraji-
Benchekroun et al., 2005; Glorioso et al., 2011). Future studies
directly manipulating the Frem3 gene in animal models would
be needed to elucidate the role of this gene in normal and
pathological brain function.
While both rs7676614 and rs1391187 were found to modulate
FREM3 gene expression in postmortem brain tissue, the precise
molecular mechanisms via which these polymorphisms may
exert their effects are unclear. Both rs7676614 and rs1391187, as
well as their respective proxy SNPs rs6537170 and rs1909022, are
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intronic; thus, theymay be involved in regulating alternative gene
splicing. However, follow-up molecular genetic studies would be
necessary to confirm this conjecture.
This study is not without its limitations. First, in order to
ensure adequate statistical power and consistency with prior
genetic association studies, we focused our analyses on non-
Hispanic Caucasian individuals as they were the largest single
ethnic group represented across samples. However, future studies
should incorporate other ethnicities in order to more fully
characterize the role of FREM3 on depression risk. In addition,
while we focused our in vivo analyses on the amygdala, we were
unable to assess SNP effects on gene expression in that brain
region. Prior work has demonstrated age-related decreases in
FREM3 expression in the amygdala and ACC (Glorioso et al.,
2011), so it may be reasonable to assume that the cis-eQTL effect
observed here also occur in the amygdala, although this will need
to be tested directly. Indeed, drawing on prior work suggesting a
general convergence of depression-associated molecular pathway
dysregulation across diverse brain regions such as the ACC
(Tripp et al., 2011), dorsolateral prefrontal cortex (dlPFC) (Sibille
et al., 2011), and the amygdala (Sibille et al., 2009; Guilloux
et al., 2012), we believe FREM3 genetic variation would similarly
impact expression patterns throughout the majority of cortical
structures implicated in depression. Detailed molecular studies
utilizing samples collected from different brain regions, ideally
within the same individuals, would be necessary to test this
conjecture.
In addition, while significant, the phenotypic differences we
observed among genotype groups in our in vivo cohort were
relatively small in size. Thismay be due to the fact that our sample
consisted of high-functioning young adults with higher than
average IQ, who were mostly free of current or past depressive
symptomatology (Supplementary Table 1). Nonetheless, the fact
that significant, albeit small, genetic differences emerged across
multiple depression-relevant phenotypes even in this young and
highly resilient sample may suggest that a potentially greater
contribution of FREM3 to depression risk could be unmasked in
older and/or longitudinal samples, as well as those enriched for
psychopathology. Our results should be interpreted with caution
until confirmed by future research in such samples.
Last but not least, we focused on two polymorphic loci within
a single gene, while our phenotypes of interest are known to be
highly polygenic in nature. In this study, however, we did not set
out to exhaustively explain phenotypic variability, but, rather, to
illustrate how convergent results from multi-modal mechanistic
follow-up studies and partial replications of suggestive GWAS
hits may serve to improve biological knowledge of depression
risk pathways. This knowledge can in turn be used to inform
and guide future GWAS through phenotypic refinement or the
enhancement of emergent variant prioritization techniques (e.g.,
Gagliano et al., 2014). Such synergy between large-scale genetic
association studies and more targeted mechanistic approaches
may not only offer better opportunities for the discovery of
novel risk variants, but also promote an increasingly detailed
delineation of biological pathways of risk, which may in turn
open novel avenues for early individualized treatment and,
possibly, prevention.
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